RxDoctor Payments Data

Amy Patel

Medical · Plymouth Meeting, PANPI 1528491958

Payments from drug & device makers

$4,411in general payments, 2019–2025

Across 222 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$786
  • Otsuka America Pharmaceutical, Inc.$606
  • UCB, Inc.$289
  • Neurocrine Biosciences, Inc.$253
  • Lilly USA, LLC$243
  • Sumitomo Pharma America, Inc.$157
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$4,11193%
  • Education$3007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,411 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$80,455
Medicare patients
226
Services billed
846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$57,865
JanuviaSitagliptin Phosphate64$56,870
OzempicSemaglutide33$44,705
FarxigaDapagliflozin Propanediol34$34,000
MounjaroTirzepatide24$30,112
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$21,226
MyrbetriqMirabegron17$18,226
XareltoRivaroxaban20$18,207
GemtesaVibegron27$17,447
JardianceEmpagliflozin21$15,588
TradjentaLinagliptin16$12,112
RestasisCyclosporine12$8,173
Breo ElliptaFluticasone/Vilanterol17$7,935
Levemir FlexpenInsulin Detemir26$5,936
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$5,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$141$57,86551 claims
MerckJanuvia$15$56,87064 claims
Novo NordiskOzempic$147$44,70533 claims
AstraZenecaFarxiga$115$34,00034 claims
Lilly USA, LLCMounjaro$243$30,11224 claims
GSKTrelegy Ellipta, Breo Ellipta$21$29,16243 claims
Boehringer IngelheimJardiance, Tradjenta$50$27,70037 claims
Astellas Pharma US IncMyrbetriq$33$18,22617 claims
Johnson & JohnsonXarelto$98$18,20720 claims
Sumitomo Pharma America, Inc.Gemtesa$157$17,44727 claims
AbbVieRestasis, Synthroid$138$10,30130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →